Press releases

11 Sep, 2020

Q-linea enters into an agreement with Hvidovre Hospital as a participant in the clinical study

Q-linea AB (publ) (OMX:QLINEA), today announced that Hvidovre Hospital in Denmark will participate in the company's European pivotal clinical study, which will start in the autumn of 2020. Through the...

4 Sep, 2020

Q-linea installs the first ASTar system at Uppsala University Hospital

Q-linea AB (publ) (OMX: QLINEA), today announced that an ASTar® instrument is now being used for beta testing at Uppsala University Hospital and that the hospital will participate in...

16 Jul, 2020

INTERIM REPORT 1 JANUARY – 30 JUNE 2020

Strong study results and virtual presentation of ASTar Second quarter, 1 April –30 June 2020 Net sales amounted to SEK 0.1 million (0.5). The operating result totalled SEK...

9 Jul, 2020

Invitation to presentation of Q-linea’s Interim report Q2-2020 on July 16, 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s interim report for the period January – June 2020 on Thursday, July 16, 2020 at 07:30 a.m. CET.   Q-linea...

30 Jun, 2020

Change in the number of shares and votes in Q-linea AB

Q-linea AB (publ) (”Q-linea” or ”the Company”), today announced that the number of shares and votes in Q-linea has increased during the month of June due to the direct...

2 Jun, 2020

Q-linea has carried out a directed issue of 4 million shares, raising proceeds of SEK 270 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR THE UNITED STATES OF AMERICA OR...

2 Jun, 2020

Q-linea announces intention to carry out a directed share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR THE UNITED STATES OF AMERICA OR...

26 May, 2020

BULLETIN FROM ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

Q-linea AB (publ) (OMX:QLINEA), Today on 26 May 2020, Q-linea AB (publ) (the “Company”) held its annual general meeting for the financial year 2019 in Uppsala, whereby the resolutions...

25 May, 2020

Webinar Friday June 5th: How can we improve infection diagnostics with ASTar

Q-linea AB (publ) (OMX: QLINEA), invites you to a webinar on June 5th at 2pm and 7pm CEST with presentations by CEO Jonas Jarvius, Research Director Mats Gullberg and...

12 May, 2020

Q-linea announces positive results from prospective study with ASTar

Q-linea AB (publ) (OMX: QLINEA), today announced positive results from a prospective patient study conducted together with Uppsala University Hospital. In the study, the ASTar system analyzed samples from...

7 May, 2020

INTERIM REPORT 1 JANUARY – 31 MARCH 2020

Q-linea signs global partnership with Thermo Fisher Scientific for commercialization of ASTar First quarter, 1 January –31 March 2020 Net sales amounted to SEK 0.2 million (0.4). The operating...

29 Apr, 2020

Invitation to presentation of Q-linea’s Interim report Q1-2020 on May 7, 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s interim report for the period January – March 2020 on Thursday, May 7, 2020 at 07:30 a.m. CET.   Q-linea...

27 Apr, 2020

NOTICE OF ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

The shareholders in Q-linea AB (publ), reg. no. 556729-0217 (the “Company”) are hereby convened to the annual general meeting on Tuesday 26 May 2020, at 4 pm in Konferens...

24 Apr, 2020

The proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors

The nomination committee of Q-linea AB (publ) submits the following proposals to be presented at the annual general meeting of shareholders to be held on 26 May 2020, with...

17 Apr, 2020

Q-linea publish the Annual report for 2019

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today that the Annual Report for the 2019 fiscal year has been published. The Annual Report is attached and can also be...

26 Mar, 2020

Q-linea has solved the component problem

Q-linea AB (publ) (OMX: QLINEA), today announced that the problem discovered in October last year has now been solved. With respect to the component that previously caused a delay...

13 Feb, 2020

YEAR-END REPORT 1 JANUARY – 31 DECEMBER 2019

Q-linea signs global partnership with Thermo Fisher Scientific for commercialization of ASTar intensifies ahead of ASTar launch Fourth quarter, 1 October–31 December 2019 Net sales amounted to SEK 0.0 million...

12 Feb, 2020

Q-linea signs global partnership with Thermo Fisher Scientific for commercialization of ASTar

Q-linea AB (publ) (OMX: QLINEA), today announced that the company has entered into a worldwide exclusive partnership with Thermo Fisher Scientific for the commercialization of ASTar. “We are very happy...

6 Feb, 2020

Invitation to presentation of Q-linea’s Year End Report Q4-2019 on February 13, 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Year End Report for the period January – December 2019 on Thursday, February 13, 2020 at 07:30 a.m. CET....

31 Jan, 2020

Change in the number of shares and votes in Q-linea AB

Q-linea AB (publ) (”Q-linea” or ”the Company”), today announced that the number of shares and votes in Q-linea has increased during the month of January due to subscription of...

7 Nov, 2019

INTERIM REPORT 1 JANUARY – 30 SEPTEMBER 2019

A quarter of intense preparation Third quarter, 1 July - 30 September 2019 Net sales amounted to SEK 0.0 million (0.3). The operating result totalled SEK -35.8 million (-28.8)....

31 Oct, 2019

Invitation to presentation of Q-linea’s Interim Report Q3-2019 on November 7, 2019

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim Report for the period January – September 2019 on Thursday, November 7, 2019 at 07:30 a.m. CET. Q-linea...

30 Oct, 2019

Q-linea receives positive response from the FDA for the design of the company’s planned clinical study in the USA

Q-linea AB (publ) (OMX: QLINEA, announced today that the company has received the official response including a number of clarifications and very positive feedback from the US Food and...

22 Oct, 2019

Q-linea postpones start of the clinical trials

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), today announced that the clinical trials, in the United States and Europe, for the company's first product ASTar® are expected to begin in the second half...

3 Sep, 2019

Q-linea strengthens management team

UPPSALA, Sweden, 3 September, 2019 - Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), a diagnostic company focused on developing and delivering solutions to accurately and rapidly diagnose infectious diseases, today announced Thomas Fritz has been appointed the...

31 Jul, 2019

Change in the number of shares and votes in Q-linea AB

Q-linea AB (publ) (”Q-linea” or ”the Company”), today announced that the number of shares and votes in Q-linea has increased during the month of July due to the new...

18 Jul, 2019

INTERIM REPORT 1 JANUARY – 30 JUNE 2019

Launch preparations continue Net sales amounted to SEK 0.5 million (0.3). The operating result totalled SEK -44.5 million (-35.7). The company reported a loss after tax of SEK -44.0 million...

12 Jul, 2019

Q-linea strengthens management team

UPPSALA, Sweden, 12 July, 2019 - Q-linea AB (publ) (Nasdaq Stockholm:QLINEA), a diagnostic company focused on developing and delivering solutions to accurately and rapidly diagnose infectious diseases, today announced...

11 Jul, 2019

Invitation to presentation of Q-linea’s Interim Report Q2-2019 on July 18, 2019

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim Report for the period January – June 2019 on Thursday, July 18, 2019 at 07:30 a.m. CET. Q-linea...

1 Jul, 2019

Issue and repurchase of class C shares for incentive program

By virtue of authorization from the annual general meeting held on 22 May 2019, the board of directors of Q-linea AB (publ) (“Q-linea”) has resolved to issue 117,424 class...

22 May, 2019

BULLETIN FROM ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

Today on 22 May 2019, Q-linea AB (publ) (Nasdaq Stockholm: QLINEA) held its annual general meeting for the financial year 2018 in Uppsala, whereby the following resolutions were adopted. For...

3 May, 2019

INTERIM REPORT 1 JANUARY – 31 MARCH 2019

Final version of ASTar shows favourable results and garners positive reception Quarter: January–March 2019 Net sales amounted to SEK 0.4 million (0.3). The operating result totalled SEK -36.7 million (-23.9). The...

26 Apr, 2019

Invitation to presentation of Q-linea’s Interim Report Q1-2019 on May 3, 2019

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim Report for the period January – March 2019 on Friday, May 3, 2019 at 07:30 a.m. CET.Q-linea invites...

18 Apr, 2019

NOTICE OF ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

The shareholders in Q-linea AB (publ), reg. no. 556729-0217 (the “Company”) are hereby convened to the annual general meeting on Wednesday 22 May 2019, at 4 pm in Konferens...

17 Apr, 2019

Q-linea publish the Annual report for 2018

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today that the Annual Report for the 2018 fiscal year has been published. The Annual Report is attached and can also be...

15 Apr, 2019

Q-linea’s ASTar – a success on ECCMID

Q-linea AB (publ) (OMX: QLINEA), a diagnostic company focused on developing and delivering solutions to accurately and rapidly diagnose infectious diseases, now presents the final design of ASTar for...

12 Apr, 2019

The proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today the proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors. The nomination committee...

29 Mar, 2019

Change in the number of shares and votes in Q-linea AB

Q-linea AB (publ) (”Q-linea” or ”the Company”), today announced that the number of shares and votes in Q-linea has increased during the month of March due to the new...

14 Mar, 2019

Q-linea can reach its main market faster than planned

Q-linea AB (publ) (OMX: QLINEA), today announced that the company's first product ASTar™ is expected to launch on the company’s main market, the U.S., three to four months than...

14 Feb, 2019

YEAR-END REPORT 1 JANUARY–31 DECEMBER 2018

Successful capital raise and IPO on Nasdaq Stockholm Net sales amounted to SEK 0.3 million (1.5). Operating result totalled SEK -39.0 million (-21.8). The company reported a loss after tax of SEK...

28 Dec, 2018

Change in the number of shares and votes in Q-linea AB

Q-linea AB (publ) (”Q-linea” or ”the Company”), today announced that the number of shares and votes in Q-linea has increased during the month of December due to the new...